Neovasc Inc (US) (NVCN) Given Average Rating of “Hold” by Analysts

Shares of Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) have been assigned a consensus rating of “Hold” from the six research firms that are currently covering the stock, reports. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $3.35.

NVCN has been the topic of several analyst reports. ValuEngine lowered Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Canaccord Genuity reaffirmed a “buy” rating and issued a $1.05 target price on shares of Neovasc Inc (US) in a research report on Friday, January 19th. Finally, Zacks Investment Research lowered Neovasc Inc (US) from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st.

Shares of Neovasc Inc (NASDAQ NVCN) opened at $0.35 on Tuesday. Neovasc Inc has a 52-week low of $0.31 and a 52-week high of $2.12. The firm has a market capitalization of $26.83, a price-to-earnings ratio of 1.46 and a beta of -0.24.

Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) last issued its earnings results on Tuesday, November 14th. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.04). Neovasc Inc (US) had a negative return on equity of 85.81% and a net margin of 268.35%. research analysts predict that Neovasc Inc will post -0.21 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Neovasc Inc (US) stock. Virtu KCG Holdings LLC purchased a new stake in shares of Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 108,132 shares of the medical equipment provider’s stock, valued at approximately $149,000. Virtu KCG Holdings LLC owned 0.14% of Neovasc Inc (US) as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 19.03% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Neovasc Inc (US) (NVCN) Given Average Rating of “Hold” by Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at

About Neovasc Inc (US)

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with's FREE daily email newsletter.

Leave a Reply